Alignment Healthcare, Inc. (ALHC)
NASDAQHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
$13.54-0.07%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Healthcare PlansSnapshot 2026-09-04
QuarterlyIQ Insights · ALHC
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks ALHC against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 3 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue expanding Medicare Advantage membership to increase scale and revenue.
Stated as a priority in 2 of last 2 quarters. Membership grew 31.5% year-over-year to approximately 294,100 in 2026-Q2. Management raised full-year membership guidance to 298,000-301,000. The trajectory is delivering with strong growth and raised outlook.
“Grows Medicare Advantage membership 31.5% year-over-year to approximately 294,100 members”
“Raises the midpoint of all full-year guidance metrics: membership, revenue, adjusted gross profit and adjusted EBITDA”
Drive revenue growth and raise full-year revenue guidance reflecting business expansion.
Stated as a priority in 3 of last 3 quarters. Revenue grew from $1.015 billion in 2025-Q2 to $1.336 billion in 2026-Q2, a 31.6% increase. Full-year revenue guidance was raised from $5.14-$5.19 billion in 2025-Q4 to $5.195-$5.225 billion in 2026-Q2. The trajectory is delivering with strong growth and raised guidance.
“Total revenue was $1,335.6 million, up 31.6% year-over-year”
Focus on improving adjusted gross profit and adjusted EBITDA margins to enhance profitability.
Stated as a priority in 2 of last 2 quarters. Adjusted gross profit increased 35.3% year-over-year to $182.9 million in 2026-Q2. Adjusted EBITDA grew 48.4% year-over-year to $68.1 million in the same quarter. Management raised full-year guidance for these metrics, indicating delivering trajectory.
“Adjusted gross profit was $182.9 million, up 35.3% year-over-year, and adjusted EBITDA of $68.1 million grew 48.4% year-over-year”
Over the trailing year it converted 0.53x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity, the broad stock market (low R² over the window).
13 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Raises the midpoint of all guidance metrics: membership, revenue, adjusted gross profit and adjusted EBITDA”
“Introduces 2026 revenue guidance of $5.14 billion to $5.19 billion”
“Raises the midpoint of all full-year guidance metrics: membership, revenue, adjusted gross profit and adjusted EBITDA”